NEW YORK, December 18, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting AbbVie Inc. (NYSE: ABBV), Baxter International Inc. (NYSE: BAX), The Cooper Companies, Inc. (NYSE: COO), ViroPharma Inc. (NASDAQ: VPHM), and Varian Medical Systems Inc. (NYSE: VAR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AbbVie Inc. Research Report
On December 12, 2013, AbbVie Inc. (AbbVie) announced that its Board of Directors has declared a quarterly cash dividend of $0.40 per share. According to AbbVie, the aforesaid cash dividend will be paid on February 14, 2013 to stockholders of record at the close of business on January 15, 2014. The Company further informed that in 2013, it has been named into the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/273c_ABBV
--
Baxter International Inc. Research Report
On December 10, 2013, Baxter International Inc. (Baxter) announced that the Company has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the approval of OBI-1, a recombinant antihemophilic porcine sequence factor VIII, in patients with acquired hemophilia A. Baxter stated that it presented phase 2/3 data supporting the submission at the American Society of Hematology (ASH) 55th Annual Meeting in New Orleans, Louisiana. The Company informed that the primary efficacy endpoint of the study was defined by clinical assessment as effective or partially effective control of bleeding and FVIII activity levels at 24 hours after initiation of OBI-1therapy. Baxter added that all patients in the study responded positively (14 effective / 4 partially effective) in the first 24 hours, based on clinical assessment and FVIII activity levels. Ludwig Hantson, Ph.D., President of Baxter's BioScience Organization, said, "Completing the BLA submission for OBI-1 in nine months following Baxter's acquisition of the molecule reflects our continuing commitment to advancing the care of hemophilia patients and extending our expertise and leadership in this category. This program has the potential to bring a new treatment option to the acquired hemophilia patient population, which has limited treatment options available today." The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/163d_BAX
--
The Cooper Companies, Inc. Research Report
On December 12, 2013, The Cooper Companies, Inc. (Cooper) announced that its Board of Directors has authorized the repurchase of up to an additional $200.0 million of common stock under the existing share repurchase program. The Company added that the aforesaid approval authorizes Cooper to repurchase up to $500.0 million of its common stock. According to the Company, Cooper's share repurchase program has $261.5 million of remaining availability and no expiration date. The Full Research Report on The Cooper Companies, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/9cde_COO
--
ViroPharma Inc. Research Report
On November 11, 2013, ViroPharma Inc. (ViroPharma) and Shire plc (Shire) jointly announced that their Boards of Directors have unanimously approved a merger agreement between the duos. According to the Companies, pursuant to the terms of the agreement, Shire will acquire all the outstanding shares of ViroPharma for $50 per share in cash, for a total consideration of c.$4.2 billion. The two Companies added that the $50 per share purchase price represents a 27% premium to ViroPharma's closing price on November 8, 2013, and a 64% premium to ViroPharma's unaffected share price of $30.47 on September 12, 2013. Commenting on the merger, Vincent J. Milano, ViroPharma's CEO, said, "We are pleased to announce our merger with Shire, which like ViroPharma, is focused on developing products for patients suffering from rare diseases. After thoroughly evaluating our strategic options we determined that this transaction is in the best interests of ViroPharma, our shareholders and our patients. By joining with Shire, ViroPharma will become part of a larger, more diverse biopharmaceutical company and will benefit from Shire's innovation, scale and global reach. We will have access to resources to expand product distribution, giving us a platform to provide our crucial therapies, such as CINRYZE, to more patients than ever before. We look forward to working with Shire's team and to being part of an even stronger, more geographically diverse organization." The Full Research Report on ViroPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/c730_VPHM
--
Varian Medical Systems Inc. Research Report
On December 10, 2013, Varian Medical Systems Inc. (Varian Medical Systems) announced that it will report its Q1 FY 2014 results on January 22, 2014, after the close of trading hours. The Company said that the results release will be followed by a teleconference on the same day at 2:00 p.m. PT. Varian Medical Systems added that the news release regarding its Q1 FY 2014 results and a link to the conference call webcast will be available on its Company website. The Full Research Report on Varian Medical Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/bd48_VAR
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
